Mavorixafor

Contraindicated

Mavorixafor Acetaminophen And Codeine Capital® & Codeine Explained Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Amitriptyline Elavil Explained Increased CYP2D6 substrate exposure, increased risk of CYP2D6-related adverse events and an increased risk of QT interval prolonga... Details Mavorixafor Aripiprazole Injection Abilify Increased CYP2D6 substrate exposure, increased risk of CYP2D6-related adverse events and an increased risk of QT interval prolonga... Details Mavorixafor Brexpiprazole Rexulti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Deutetrabenazine Austedo Increased CYP2D6 substrate exposure, increased risk of CYP2D6-related adverse events and an increased risk of QT interval prolonga... Details Mavorixafor Doxorubicin Adriamycin Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Flecainide Tambocor® Increased CYP2D6 substrate exposure, increased risk of CYP2D6-related adverse events and an increased risk of QT interval prolonga... Details Mavorixafor Gefitinib Iressa Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Loratadine Agistam® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Maprotiline Ludiomil® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Metoclopramide Injection Gimoti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Metoclopramide Nasal Spray Gimoti Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Mexiletine Mexitil® Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details Mavorixafor Nebivolol Bystolic Increased CYP2D6 substrate exposure and an increased risk of CYP2D6 substrate-related adverse events Details

Major

Mavorixafor Clindamycin ANTIROBE Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Mavorixafor Sertraline Explained An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Buprenorphine Belbuca Explained An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Relugolix Orgovyx Explained Increased relugolix exposure and an increased risk of QT interval prolongation Details Mavorixafor Colchicine Colcrys Explained Increased CYP3A4 and P-gp substrate with NTI exposure and an increased risk of CYP3A4 and P-gp with NTI-related adverse events Details Mavorixafor Abemaciclib Verzenio Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Mavorixafor Abrocitinib Cibinqo Explained Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Mavorixafor Acalabrutinib Calquence Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Mavorixafor Amisulpride Injection Barhemsys An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Arsenic Trioxide Trisenox An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Azithromycin AzaSite Increased mavorixafor exposure, increased risk of mavorixafor-related adverse effects and an increased risk of QT interval prolong... Details Mavorixafor Atorvastatin Atorvaliq Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Mavorixafor Alfuzosin UroXatral An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Alogliptin Nesina Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Mavorixafor Anagrelide Agrylin An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Axitinib Inlyta Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Mavorixafor Bedaquiline Sirturo An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Bosutinib Bosulif Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Mavorixafor Brigatinib Alunbrig Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Mavorixafor Canagliflozin Invokana Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Mavorixafor Capmatinib Tabrecta Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Mavorixafor Captopril Capoten® Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Mavorixafor Chloroquine Aralen® An increased risk of QT interval prolongation and torsade de pointes Details Mavorixafor Clindamycin Injection ANTIROBE Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details